Simvastain affects TAFI and thrombomodulin in CAPD patients

Thrombosis and Haemostasis

Volumn 86, Issue 3, 2001, Pages 930-931

  Malyszko, J ^a   Malyszko, J S ^a   Hryszko, T ^a   Mysliwiec M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMIN; PROTHROMBIN; SIMVASTATIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN;

ADULT; BLOOD CLOT LYSIS; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; KIDNEY DISEASE; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS;

EID: 0034846463     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616154     Document Type: Letter

References (16)

1. Morbidity and mortality on maintenance hemodialysis
2. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome
3. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients
4. Bleeding and thrombosis in chronic uremia
5. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis
6. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor
7. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor
8. Assay of procarboxypeptidase U, a novel determinant of fibrinolytic cascade, in human plasma
9. Comparison of hemostatic disturbances between patients on CAPD and HD
10. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients
11. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis
12. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis
13. Plasma thrombomodulin in renal disease: Effects of renal function and proteinuria
14. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma
15. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis
16. Recent advances in statins and the kidney